Should Albumin Infusion Be Stopped?
No, albumin infusion should not be routinely stopped solely due to the presence of bilateral moderate pleural effusions in a patient with hypoalbuminemia, but the clinical context and indication for albumin must be carefully evaluated. The decision depends critically on whether this is a cirrhotic patient and what specific indication prompted albumin administration.
Clinical Context Assessment
The presence of pleural effusions with hypoalbuminemia does not automatically contraindicate albumin therapy. The key question is: Why was albumin started?
If This Is a Cirrhotic Patient:
Continue albumin if it was given for an appropriate indication 1, 2:
- Post-large volume paracentesis (>5L): Albumin at 6-8 g/L of fluid removed is strongly indicated and should be completed 1, 2
- Spontaneous bacterial peritonitis (SBP): Albumin (1.5 g/kg day 1 g/kg day 3) significantly reduces acute kidney injury (10% vs 33%) and mortality (10% vs 29%) and should be continued 1
- Hepatorenal syndrome-AKI: Albumin is the volume expander of choice and should continue with vasoconstrictors 1
Important caveat: In cirrhosis, pleural effusions (hepatic hydrothorax) are a manifestation of portal hypertension and volume overload, not necessarily caused by albumin infusion 2. The FDA label explicitly acknowledges that hyperoncotic albumin (25%) combined with diuretics may play a therapeutic role when clinical signs show hypoproteinemia WITH fluid volume overload 3.
If This Is NOT a Cirrhotic Patient:
Strongly consider stopping albumin 3, 4:
- Hypoalbuminemia alone rarely causes pleural effusions 4
- The FDA label states albumin is not justified for chronic hypoproteinemic states (chronic cirrhosis, malabsorption, protein-losing enteropathies, malnutrition) as a source of protein nutrition 3
- In non-cirrhotic conditions, albumin infusion for hypoalbuminemia alone lacks evidence for benefit and carries risk of fluid overload 3
Risk Assessment for Fluid Overload
Monitor closely for signs of circulatory overload 3:
- The FDA label warns that hyperoncotic albumin (25%) draws 3-4 times its volume from interstitial spaces into plasma, which can precipitate pulmonary edema if the patient is volume overloaded 3
- Caution must be observed in patients already showing signs of volume overload 3
- Albumin-associated lung injury, though rare, has been reported 5
Key clinical indicators to assess:
- Hemodynamic stability (blood pressure, heart rate)
- Respiratory status (oxygen requirements, work of breathing)
- Volume status (jugular venous pressure, peripheral edema, daily weights)
- Renal function and urine output
Practical Algorithm
Identify the indication: Review why albumin was started
If cirrhotic with appropriate indication (LVP >5L, SBP, HRS-AKI):
- Continue albumin as indicated
- Add loop diuretics if not already on them 2
- Monitor closely for worsening respiratory status
- Consider therapeutic thoracentesis if effusions are symptomatic
If cirrhotic WITHOUT appropriate indication:
If non-cirrhotic:
- Stop albumin immediately
- Treat underlying cause of hypoalbuminemia
- Manage pleural effusions based on etiology
- Use diuretics for volume overload
Common Pitfalls to Avoid
- Do not use albumin as "nutritional support" for chronic hypoalbuminemia—it is ineffective and wasteful 3, 6
- Do not assume pleural effusions are caused by hypoalbuminemia alone—search for other causes (infection, heart failure, malignancy) 4
- Do not continue albumin indefinitely without a clear, evidence-based indication 1, 2
- Do not ignore volume status—hyperoncotic albumin can precipitate pulmonary edema in volume-overloaded patients 3, 5
The presence of pleural effusions is not an absolute contraindication to albumin in cirrhosis when given for appropriate indications, but requires heightened vigilance for fluid overload and consideration of concurrent diuretic therapy.